Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

T- Cell Non-Hodgkin's Lymphoma, Data From a Mexican Tertiary Health Center..

Silvia Rivas-Vera, MD, Mabel Oropeza-Borges, MD, Pedro Sobrevilla-Calvo, MD

Blood (2009) 114 (22): 5030.

https://doi.org/10.1182/blood.V114.22.5030.5030

Published: 2009

Journal Articles

Central Nervous System Involvement in Primary Nasal Lymphoma.

Nora Sobrevilla-Moreno, MD, Marcela Janka-Zires, MD, Pedro Sobrevilla-Calvo, MD, Luis Durazo-Cons, MD, Silvia Rivas-Vera, MD

Blood (2009) 114 (22): 2940.

https://doi.org/10.1182/blood.V114.22.2940.2940

Published: 2009

Journal Articles

Assessment of FDG-PET Imaging in T-Cell and NK-Cell Lymphomas

Juan Chalapud-Revelo, MD, Pedro Sobrevilla-Calvo, MD, Cadena-Eumaña Carlos, Rivas-Vera Silvia, Lopez-Navarro Omar, Labardini Juan

Blood (2008) 112 (11): 5305.

https://doi.org/10.1182/blood.V112.11.5305.5305

Published: 2008

Journal Articles

Intrapleural Rituximab (R) Is Effective in Refractory Pleural Effusion Due to Non- Hodgkin’s Lymphoma

Silvia Rivas-Vera, MD, Carlos Cadena-Eumaña, MD, Juan Chalapud-Revelo, MD, Adriana Aguilar-Navarro, MD, Pedro Sobrevilla-Calvo, MD, Cristina Lievano-Torres

Blood (2008) 112 (11): 5004.

https://doi.org/10.1182/blood.V112.11.5004.5004

Published: 2008

Journal Articles

Marked Improvement in Detecting the Number of Involved Nodal Areas in Lymphoma, Using 18 F- FDG - PET and CT Scan.

Juan Chalapud, MD, Pedro Sobrevilla-Calvo, MD, Silvia Rivas-Vera, MD, Javier Altamirano-Levy, MD

Blood (2005) 106 (11): 1344.

https://doi.org/10.1182/blood.V106.11.1344.1344

Published: 2005

Journal Articles

High Incidence of Bcl-2/IgH Rearrangement in Mexican Patients With Follicular Lymphoma and Its Relevance as a Marker for Minimal Residual Disease.

Rosa M. Arana, QFB, Pedro Sobrevilla-Calvo, MD, Silvia Rivas-Vera, MD, Enrique Baez, MD, Severiano Baltazar, MD, Jorge Duque, MD, Ignacio Gregorio, MD, Francisco Tripp, MD, Oscar Garces, MD, Luis Aguilar, MD, Luis Flores, MD

Blood (2005) 106 (11): 4493.

https://doi.org/10.1182/blood.V106.11.4493.4493

Published: 2005

Journal Articles

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Silvia Rivas-Vera, MD, Enrique Baez, MD, Pedro Sobrevilla-Calvo, MD, Severiano Baltazar, MD, Francisco Tripp, MD, Jorge Vela, MD, Oscar Garces, MD, Luis Aguilar, MD, Gregorio Ignacio, MD, Jorge Duque, MD, Petty Rodriguez, MD, Gustavo Reyes, MD

Blood (2005) 106 (11): 2431.

https://doi.org/10.1182/blood.V106.11.2431.2431

Published: 2005

NARROW

T- Cell Non-Hodgkin's Lymphoma, Data From a Mexican Tertiary Health Center..

Central Nervous System Involvement in Primary Nasal Lymphoma.

Assessment of FDG-PET Imaging in T-Cell and NK-Cell Lymphomas

Intrapleural Rituximab (R) Is Effective in Refractory Pleural Effusion Due to Non- Hodgkin’s Lymphoma

Marked Improvement in Detecting the Number of Involved Nodal Areas in Lymphoma, Using 18 F- FDG - PET and CT Scan.

High Incidence of Bcl-2/IgH Rearrangement in Mexican Patients With Follicular Lymphoma and Its Relevance as a Marker for Minimal Residual Disease.

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Email alerts

ASH Publications

American Society of Hematology

T- Cell Non-Hodgkin's Lymphoma, Data From a Mexican Tertiary Health Center..

Central Nervous System Involvement in Primary Nasal Lymphoma.

Assessment of FDG-PET Imaging in T-Cell and NK-Cell Lymphomas

Intrapleural Rituximab (R) Is Effective in Refractory Pleural Effusion Due to Non- Hodgkin’s Lymphoma

Marked Improvement in Detecting the Number of Involved Nodal Areas in Lymphoma, Using 18 F- FDG - PET and CT Scan.

High Incidence of Bcl-2/IgH Rearrangement in Mexican Patients With Follicular Lymphoma and Its Relevance as a Marker for Minimal Residual Disease.

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only